施乐辉(SNN)高管介绍_美股行情_同花顺金融网

来自 : stockpage.10jqka.com.cn/SNN/ma 发布时间：2021-03-26

Michael Friedman,2003年12月开始就是董事。2003年就是希望城国家医学中心（the City of Hope National Medical Center）的首席执行官和总裁。2001年9月到2003年4月，他是法玛西亚公司（Pharmacia Corporation）研究和发展部，医疗和公共政策部的高级副总裁。1999年7月到2001年9月，他是赛尔公司（Searle 孟山都公司Monsanto Company的子公司）的高级副总裁。1995年到1999年6月，他是食品和药物管理局（Food and Drug Administration）营运部的副税务长。1997年到1998年，他是代理专员和副专员。他获得路易斯安那新奥尔良的杜兰大学（Tulane University）的文学学士学位，是优等生。他获得来自德克萨斯大学（the University of Texas）西南医学院的医学博士学位。

Michael Friedman, M.D. has served as one of the company\'s directors since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration FDA, later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004 Dr. Friedman has served on the Independent Citizens Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Smith & Nephew plc. and Intuitive Surgical, Inc. He also serves on the Board of Trustees for Tulane University. Michael Friedman,2003年12月开始就是董事。2003年就是希望城国家医学中心（the City of Hope National Medical Center）的首席执行官和总裁。2001年9月到2003年4月，他是法玛西亚公司（Pharmacia Corporation）研究和发展部，医疗和公共政策部的高级副总裁。1999年7月到2001年9月，他是赛尔公司（Searle 孟山都公司Monsanto Company的子公司）的高级副总裁。1995年到1999年6月，他是食品和药物管理局（Food and Drug Administration）营运部的副税务长。1997年到1998年，他是代理专员和副专员。他获得路易斯安那新奥尔良的杜兰大学（Tulane University）的文学学士学位，是优等生。他获得来自德克萨斯大学（the University of Texas）西南医学院的医学博士学位。 Michael Friedman, M.D. has served as one of the company\'s directors since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration FDA, later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004 Dr. Friedman has served on the Independent Citizens Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Smith & Nephew plc. and Intuitive Surgical, Inc. He also serves on the Board of Trustees for Tulane University.